Characterisation of the clinical and activated T cell response to repeat delayed-type hypersensitivity skin challenges in human subjects, with KLH and PPD, as a potential model to test T cell-targeted therapies

详细信息    查看全文

• 作者：Alexandra Belson ; Tim Schmidt ; Disala Fernando ; Kelly Hardes…
• 关键词：DTH ; Skin challenge ; T cell ; Skin blister ; KLH ; PPD
• 刊名：Inflammation Research
• 出版年：2016
• 出版时间：May 2016
• 年：2016
• 卷：65
• 期：5
• 页码：389-404
• 全文大小：4,086 KB
• 参考文献：1.Palestine AG, Roberge F, Charous BL, Lane HC, Fauci AS, Nussenblatt RB. The effect of cyclosporine on immunization with tetanus and keyhole limpet hemocyanin (KLH) in humans. J Clin Immunol. 1985;5:115–21.CrossRef PubMed
  2.Amlot L, Hayes AS, Gray D, Gordon-Smith EC, Humphrey JH. Human responses in vivo to protein (KLH) and polysaccharide (DNP-Ficoll) neoantigens: normal subjects compared to bone marrow transplant patients on cyclosporine. Clin Exp Immunol. 1986;64:125–35.PubMed PubMedCentral
  3.Ellis CN, Fradin MS, Messana JM, Brown MD, Siegel MT, Hartley AH, Rocher LL, Wheeler S, Hamilton TA, Parish TG, Ellis-Madu M, Duell E, Annesley TM, Cooper KD, Voorhees JJ. Cyclosporine for plaque-type psoriasis: results of a multidose, double-blind trial. N Engl J Med. 1991;324:277–84.CrossRef PubMed
  4.Rentenaar RJ, van Diepen FNJ, Meijer RT, Surachno S, Wilmink JM, Schellekens PTA, Pals ST, van Lier RAW, ten Berge IJM. Immune responsiveness in renal transplant recipients: mycophenolic acid severely depresses humoral immunity in vivo. Kidney Int. 2002;62:319–28.CrossRef PubMed
  5.Krueger JG, Ochs HD, Patel P, Gilkerson E, Guttman-Yassky E, et al. Effect of therapeutic integrin (CD11a) blockade with efalizumab on immune responses to model antigens in humans: results of a randomized, single blind study. J Invest Dermatol. 2008;128:2615–24.CrossRef PubMed
  6.Boulton C, Meiser K, David OJ, Schmouder R. Pharmacodynamic effects of steady-state fingolimod on antibody response in healthy volunteers: a 4-week, randomized, placebocontrolled, parallel-group, multiple-dose study. J Clin Pharmacol. 2012;52(12):1879–90 Epub 2011 Dec 15.CrossRef PubMed
  7.Dumont FJ. Fontolizumab protein design labs. Curr Opin Investig Drugs. 2005;6(5):537–44.PubMed
  8.Moreland LW, Bucy RP, Weinblatt ME, Mohler KM, Spencer-Green GT, Chatham WW. Immune function in patients with rheumatoid arthritis treated with etanercept. Clin Immunol. 2002;103(1):13–21.CrossRef PubMed
  9.Hatemi G, Melikoglu M, Fresko I, Masatlioglu S, Tascilar K, Yazici H. Infliximab does not suppress the tuberculin skin test (purified protein derivative). J Rheumatol. 2007;34(3):474–80.PubMed
  10.Joven BE, Almodóvar R, Galindo M, Mateo I, Pablos JL. Does anti-tumour necrosis factor α treatment modify the tuberculin PPD response? Ann Rheum Dis. 2006;65:699.CrossRef PubMed PubMedCentral
  11.Bingham CO, Looney RJ, Deodhar A, Halsey N, Greenwald M, Codding C, Trzaskona B, Martin F, Agarwal S, Kelman A. Immunization responses in rheumatoid arthritis patients treated with rituximab. Arthritis Rheum. 2010;62(1):64–74.CrossRef PubMed
  12.Kiistala U. Suction blister device for separation of viable epidermis from dermis. J Invest Dermatol. 1968;50(2):129–37.CrossRef PubMed
  13.Akbar AN, Reed JR, Lacy KE, Jackson SE, Vukmanovic-Stejic M, Rustin MHA. Investigation of the cutaneous response to recall antigens in vivo. Clin Exp Immunol. 2013;173:163–72.CrossRef PubMed PubMedCentral
  14.Harris JR, Markl J. Keyhole limpet hemocyanin (KLH): a biomedical review. Micron. 1999;30:597–623.CrossRef PubMed
  15.Dickson MC, Dewit O, Peters G, Norton N, McHugh S, Davis B, Perry H, Lyons A, McSherry I, Binks M. Immunisation challenges with keyhole limpet haemocyanin (KLH) and bacteriophage PhiX174; potential model for modeling in vivo pharmacodynamic effects. BSI Poster abstract. 2014.
  16.Vukmanovic-Stejic M, Reed JR, Lacy KE, Rustin MHA, Akbar AN. Mantoux test as a model for a secondary immune response in humans. Immunol Lett. 2006;107:93–101.CrossRef PubMed
  17.Reed JR, Vukmanovic-Stejic M, Fletcher JM, Soares MV, Cook JE, Orteu CH, Jackson SE, et al. Telomere erosion in memory T cells induced by telomerase inhibition at the site of antigenic challenge in vivo. J Exp Med. 2004;199:1433–43.CrossRef PubMed PubMedCentral
  18.Sierro S, Romero P, Speiser D. The CD4-like molecule LAG-3, biology and therapeutic applications. Expert Opin Ther Targets. 2011;15:91–101.CrossRef PubMed
  19.Workman CJ, Rice DS, Dugger KJ, Kurschner C, Vignali DA. Phenotypic analysis of the murine CD4-related glycoprotein, CD223 (LAG-3). Eur J Immunol. 2002;32:2255–63.CrossRef PubMed
  20.Poirier N, Haudebourg T, Brignone C, Dilek N, Hervouet J, Minault D, Coulon F, de Silly RV, Triebe F, Blancho G, Vanhove B. Antibody-mediated depletion of lymphocyte-activation gene-3 (LAG-3+)-activated T lymphocytes prevents delayed-type hypersensitivity in non-human primates. Clin Exp Immunol. 2011;164:265–74.CrossRef PubMed PubMedCentral
  21.Sokal JE. Measurement of delayed skin-test responses (Editorial). N Engl J Med. 1975;293:501–2.CrossRef PubMed
  22.Maddison SE, Hicklin MD, Conway BP, Kagan IG. Transfer factor: delayed hypersensitivity to Schistosoma mansoni and tuberculin in Macaca mulatta. Science. 1972;178:757–9.CrossRef PubMed
  23.Cordoba F, Wieczorek G, Preussing E, Bigaud M. Modelling of delayed type hypersensitivity (DTH) in the non-human primate (NHP). Drug Discov Today. 2008;5:63–71.CrossRef
  24.Menzies R, Vissandjee B, Rocher I, St Germain Y. The booster effect in two-step tuberculin testing among young adults in Montreal. Ann Intern Med. 1994;120:190–8.CrossRef PubMed
  25.Orteu CH, Poulter LW, Rustin MHA, Sabin CA, Salmon M, Abkar AN. The role of apoptosis in the resolution of T cell-mediated cutaneous inflammation. J Immunol. 1998;161:1619–29.PubMed
  26.Agius E, Lacy KE, Vukmanovic-Stejic M, Jagger AL, Papageorgiou AP, Hall S, Reed JR, et al. Decreased TNF-α synthesis by macrophages restricts cutaneous immunosurveillance by memory CD4+ T cells during aging. J Exp Med. 2009;206:1929–40.CrossRef PubMed PubMedCentral
  
• 作者单位：Alexandra Belson (1)
  Tim Schmidt (1)
  Disala Fernando (3)
  Kelly Hardes (2)
  Nicola Scott (1)
  Sara Brett (1)
  Deborah Clark (3)
  João Joaquim Oliveira (3)
  Bill Davis (3)
  Simon McHugh (3)
  John Stone (1)
  
  1. GlaxoSmithKline Medicines Research Centre, Gunnels Wood Road, Stevenage, SG1 2NY, UK
  3. Clinical Unit Cambridge, Addenbrooke’s Centre for Clinical Investigation, GlaxoSmithKline, Hills Road, Cambridge, CB2 0QQ, UK
  2. GlaxoSmithKline, Stockley Park West, 1-3 Iron Bridge Road, Uxbridge, Middlesex, UB11 1BT, UK
  
• 刊物类别：Biomedical and Life Sciences
• 刊物主题：Biomedicine
  Immunology
  Pharmacology and Toxicology
  Allergology
  Dermatology
  Neurology
  Rheumatology
  
• 出版者：Birkh盲user Basel
• ISSN：1420-908X

文摘

Objective To characterise the delayed-type hypersensitivity (DTH) skin reaction to repeated challenges of keyhole limpet hemocyanin (KLH) and tuberculin purified protein derivative (PPD) in healthy volunteers, as a potential model to test T cell-targeted investigational agents.